cagrilintide semaglutide combination cagrisema phase 3 2025 Novo Nordisk to present array of new portfolio data including studies with and CagriSema, expanding evidence in obesity and diabetes care at ADA Novo Nordisk's Cagrilintide shows promising

FDA-approved peptides (Saxenda, Wegovy, Zepbound) cause gastrointestinal side effects like nausea, vomiting and diarrhea in up to 80% of patients, with rare serious events including gallstones or inflammation of the pancreas

Mutations in the AIRE gene cause autoimmune polyendocrinopathy, a condition where multiple organs come under immune attack simultaneously

Glycemic control: Significant HbA1c reductions in type 2 diabetes trials [4] [9]

Traditional recovery methodssuch as ice baths, stretching, and protein intakehave their place, but many athletes are turning to more advanced tools to support performance and healing

Improves Cardiac Function: Increases cardiac output and left ventricular function independently of GH, likely through myocardial GHS-R1a activation 3